The Society for Immunotherapy of Cancer (SITC) is the world’s leading
member-driven organization specifically dedicated to improving cancer
patient outcomes by advancing the science and application of cancer
immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit
organization, serves scientists, clinicians, academicians, patients,
patient advocates, government representatives and industry leaders from
around the world. Through educational programs that foster scientific
exchange and collaboration, SITC aims to one day make the word “cure” a
reality for cancer patients everywhere.
Currently, SITC has over 1,700 members representing 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer.
Through emphasis on high-caliber scientific meetings; dedication to education and outreach activities; focus on initiatives of major importance in the field; and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community.